CN116685353A - 血管性水肿的预防和治疗 - Google Patents

血管性水肿的预防和治疗 Download PDF

Info

Publication number
CN116685353A
CN116685353A CN202180080857.7A CN202180080857A CN116685353A CN 116685353 A CN116685353 A CN 116685353A CN 202180080857 A CN202180080857 A CN 202180080857A CN 116685353 A CN116685353 A CN 116685353A
Authority
CN
China
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
dose
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180080857.7A
Other languages
English (en)
Chinese (zh)
Inventor
A·莱塞格
吕蓬
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Favaris Co ltd
Original Assignee
Favaris Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Favaris Co ltd filed Critical Favaris Co ltd
Publication of CN116685353A publication Critical patent/CN116685353A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202180080857.7A 2020-11-12 2021-11-12 血管性水肿的预防和治疗 Pending CN116685353A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20207273 2020-11-12
EP20207273.2 2020-11-12
PCT/EP2021/081493 WO2022101395A1 (en) 2020-11-12 2021-11-12 Prophylaxis and treatment of angioedema

Publications (1)

Publication Number Publication Date
CN116685353A true CN116685353A (zh) 2023-09-01

Family

ID=73401436

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180080857.7A Pending CN116685353A (zh) 2020-11-12 2021-11-12 血管性水肿的预防和治疗

Country Status (12)

Country Link
US (1) US20230338358A1 (https=)
EP (1) EP4243824B1 (https=)
JP (1) JP2023549849A (https=)
KR (1) KR20230107269A (https=)
CN (1) CN116685353A (https=)
AU (1) AU2021376885A1 (https=)
CA (1) CA3198246A1 (https=)
ES (1) ES3061585T3 (https=)
IL (1) IL302887A (https=)
MX (1) MX2023005563A (https=)
WO (1) WO2022101395A1 (https=)
ZA (1) ZA202305122B (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES3062067T3 (en) * 2022-03-25 2026-04-08 Pharvaris Gmbh Solid composition comprising solubilised bradykinin b2-receptor antagonists
TW202345810A (zh) * 2022-03-25 2023-12-01 瑞士商帕法瑞斯有限責任公司 包含緩激肽ｂ２受體拮抗劑之固態延長釋放組成物
WO2025037920A1 (ko) 2023-08-16 2025-02-20 주식회사 엘지화학 수지 조성물

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200255405A1 (en) * 2017-11-24 2020-08-13 Pharvaris Netherlands B.V. Novel bradykinin b2 receptor antagonists

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005053660A2 (en) * 2003-12-03 2005-06-16 Lifecycle Pharma A/S Pharmaceutical compositions comprising danazol
US7816383B1 (en) * 2009-12-04 2010-10-19 Intermune, Inc. Methods of administering pirfenidone therapy

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200255405A1 (en) * 2017-11-24 2020-08-13 Pharvaris Netherlands B.V. Novel bradykinin b2 receptor antagonists

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
LESAGE, ANNE: "In VitroPharmacological Profile of a New Small Molecule Bradykinin B2Receptor Antagonist", 《 FRONTIERS IN PHARMACOLOGY》, no. 11, 28 July 2020 (2020-07-28), pages 1 - 16 *
陈翔: "伊曲康唑对健康志愿者体内维胺酯药代动力学影响", 《中国药理学通报》, no. 11, 7 December 2006 (2006-12-07), pages 1390 - 1393 *

Also Published As

Publication number Publication date
EP4243824B1 (en) 2025-12-24
MX2023005563A (es) 2023-09-11
ES3061585T3 (en) 2026-04-06
WO2022101395A1 (en) 2022-05-19
ZA202305122B (en) 2024-08-28
CA3198246A1 (en) 2022-05-19
IL302887A (en) 2023-07-01
KR20230107269A (ko) 2023-07-14
EP4243824A1 (en) 2023-09-20
AU2021376885A1 (en) 2023-06-08
US20230338358A1 (en) 2023-10-26
JP2023549849A (ja) 2023-11-29
EP4243824C0 (en) 2025-12-24

Similar Documents

Publication Publication Date Title
TWI777515B (zh) 治療嗜伊紅性食道炎之方法
Chen et al. Antifungal agents
US10806735B2 (en) Use of neutrophil elastase inhibitors in liver disease
CN116685353A (zh) 血管性水肿的预防和治疗
EP4588513A2 (en) Methods of treating gout
CN107088225A (zh) 治疗法布里病的给药方案
US20230330072A1 (en) Treatment of migraine
CN112789041A (zh) 用于降低血清尿酸的组合物
US11571408B2 (en) Cancer treatment using docetaxel by controlling peak plasma levels
Everts et al. Probenecid and food effects on flucloxacillin pharmacokinetics and pharmacodynamics in healthy volunteers
KR20160118234A (ko) 만성 신장병의 진행 억제 또는 개선제
US9399036B2 (en) Methods of colchicine administration
Wang et al. Advances in pediatric pharmacology, therapeutics, and toxicology
JP7668386B2 (ja) １－（３－シアノ－１－イソプロピル－インドール－５－イル）ピラゾール－４－カルボン酸を含む薬学的組成物
HK40099091A (en) Prophylaxis and treatment of angioedema
HK40099091B (en) Prophylaxis and treatment of angioedema
Esseku et al. A randomized Phase I bioequivalence clinical trial of a paediatric fixed-dose combination antiretroviral reconstitutable suspension in healthy adult volunteers
JP2022538210A (ja) 腎機能障害患者における高アンモニア血症の治療
US20240423961A1 (en) 1h-1,2,3-triazole-4-carboxylic acids for treatment of hyperoxaluria and kidney stones
US20260124185A1 (en) Treatment of migraine
Helget et al. Efficacy and Safety of Urate Lowering Therapy (ULT) in CKD Patients With Gout: SA-PO895
WO2024133947A1 (en) Lurbinectedin and cyp3a4 inhibitor combination
HK40128278A (en) Methods of treating gout

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination